Screener
Jazz Pharmaceuticals JAZZ Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Gain on sale of priority review voucher | (122.8) | — |
| Total operating expenses | 732.3 | 953.7 |
| Income (loss) from operations | 336.6 | (55.9) |
| Interest expense, net | (39.9) | (53.7) |
| Foreign exchange gain (loss) | 2.5 | (0.2) |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | 299.2 | (109.8) |
| Income tax expense (benefit) | 6.1 | (17.8) |
| Equity in loss of investees | — | 0.5 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's interest expense?
- Jazz Pharmaceuticals (JAZZ) reported interest expense of -$39.9M in Q1 2026.
- How has Jazz Pharmaceuticals's interest expense changed year-over-year?
- Jazz Pharmaceuticals's interest expense increased by 25.7% year-over-year, from -$53.7M to -$39.9M.
- What is the long-term trend for Jazz Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's interest expense has grown at a 15.8% compound annual growth rate (CAGR), from $138.27M to $248.56M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Jazz Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude